What is polyposis?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: December 21, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

What is Polyposis?

Polyposis refers to a group of syndromes characterized by the presence of multiple polyps in the gastrointestinal tract, particularly the colon, with varying cancer risks depending on the specific syndrome and polyp histology. 1

Classification by Polyp Histology

Polyposis syndromes are classified into three main categories based on the microscopic appearance of the polyps 1:

  • Adenomatous polyposis: Polyps with dysplastic epithelium and malignant potential 1
  • Hamartomatous polyposis: Polyps with abnormal tissue architecture but originally non-neoplastic nature 1
  • Serrated polyposis: Polyps with serrated architecture 1

Major Polyposis Syndromes

Familial Adenomatous Polyposis (FAP)

FAP is the most common hereditary polyposis syndrome with a known genetic cause, affecting less than 1% of all colorectal cancer cases. 1

  • Classical FAP: Characterized by >100 adenomatous polyps throughout the colon, with nearly 100% risk of colorectal cancer by age 40 if untreated 1
  • Attenuated FAP: Presents with 10-100 adenomas, preferentially in the right colon, with later onset 1
  • Caused by germline mutations in the APC gene on chromosome 5q21, with 30-40% arising from de novo mutations 1
  • Associated extracolonic manifestations include hepatoblastoma in children, duodenal adenomas, thyroid cancer, desmoid tumors, osteomas, and dental anomalies 1

MUTYH-Associated Polyposis (MAP)

  • Recessively inherited polyposis due to biallelic mutations in the MUTYH base excision repair gene 1
  • Presents with attenuated phenotype of 10-100 adenomatous polyps 1
  • Lifetime colorectal cancer risk approximately 60% compared to 6% in the general population 1
  • Less than 5% develop extracolonic cancers 1

Juvenile Polyposis Syndrome (JPS)

JPS is characterized by hamartomatous polyps with distinctive microscopic features including dense edematous stroma, cystic mucus-filled glands, and prominent inflammatory infiltration. 2, 3

  • Occurs in approximately 1 per 100,000 newborns, making it 10 times less common than FAP 1, 2, 3
  • Diagnostic criteria require any one of: ≥5 juvenile polyps in the colorectum, juvenile polyps throughout the GI tract, or any number of juvenile polyps with positive family history 2, 3
  • Cumulative lifetime colorectal cancer risk of 39-68% and gastric cancer risk of 21% in those with gastric polyps 2, 3
  • Caused by mutations in SMAD4 (20%) or BMPR1A (20%) genes 2
  • Typical polyp numbers range from 50-200 in the colon 1, 3

Critical pitfall: The term "juvenile polyp" refers to a specific histologic type, not the age at diagnosis—solitary juvenile polyps in children are common and NOT associated with cancer risk, unlike syndromic juvenile polyposis. 2, 4

Peutz-Jeghers Syndrome (PJS)

  • Autosomal dominant syndrome with hamartomatous polyps and characteristic mucocutaneous pigmentation at the vermillion border of the lips 1
  • Polyps exhibit distinctive branching smooth muscle architecture (arborizing pattern) extending to villus tips 1
  • Predominantly affects the small intestine but also occurs in stomach and colon 1
  • Caused by mutations in the LKB1 gene on chromosome 19p 1
  • 80-500-fold excess risk of gastrointestinal cancers 1
  • Cumulative cancer risk: 1-2% by age 20, >30% by age 50, >80% by age 70 1
  • Intussusception occurs in 15% by age 10 and 50% by age 20 1

Clinical Implications

Cancer Risk Stratification

The cancer risk varies dramatically by syndrome 1, 5:

  • FAP: Nearly 100% colorectal cancer risk without prophylactic colectomy 1
  • JPS: 39-68% colorectal cancer risk, 21% gastric cancer risk 2, 3
  • MAP: 60% colorectal cancer risk 1
  • PJS: >80% cumulative cancer risk by age 70 across multiple organ systems 1

Distinguishing Features

Histopathologic examination is essential for accurate classification, as clinical presentation alone can be misleading. 6

  • Adenomatous polyps show dysplastic epithelium with nuclear abnormalities and tubular/villous architecture 2
  • Juvenile polyps have hamartomatous architecture with edematous stroma and lack smooth muscle branching 2, 4
  • Peutz-Jeghers polyps have distinctive arborizing smooth muscle pattern absent in juvenile polyps 2

Important caveat: Juvenile polyps can develop adenomatous dysplasia (8.5% show mild-moderate dysplasia, 0.3% show severe dysplasia or cancer), which can lead to misdiagnosis as FAP if comprehensive evaluation is not performed. 6

Genetic Testing Considerations

  • Full germline genetic testing should include DNA sequencing and large rearrangement analysis 1
  • Multigene panels can analyze multiple polyposis genes (APC, MUTYH, POLE, POLD1, NTHL1, SMAD4, BMPR1A) simultaneously 1
  • A large proportion of polyposis cases remain genetically unexplained despite advances in genetic testing 5

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Juvenile Polyposis Syndrome Diagnosis and Management

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Juvenile Polyposis Syndrome

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Fundic Gland Polyps and Juvenile Polyposis Syndrome

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.